UP!

AEZS $0.35   View long term graphs

Æterna Zentaris Inc.
Type
Public
Traded as NASDAQ: AEZS
TSX: AEZ
Industry Biotechnology
Headquarters Quebec, Canada
Key people
  • Prof. Juergen Engel, Ph.D.
  • Jude Dinges (COO)
Website www.aezsinc.com

Æterna Zentaris Inc. is a Quebec, Canada-based biopharmaceutical drug development company focused in oncology and endocrine therapy, currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It has over 80 employees in Canada, United States and Germany. The company is based in Canada, the development and research site is based in Germany. The company has 3 lead projects: an ongoing Phase 3 trial in multiple myeloma (a form of blood cancer) conducted under a Special Protocol Assessment (SPA): a Phase 3 trial in endometrial cancer with AEZS-108 expected to be initiated in 1Q 2013, and a New Drug Application (NDA) expected to be filed in 1Q 2013 for the approval of AEZS-130 as potentially the first oral diagnostic test for adult growth hormone deficiency (AGHD).

Perifosine: Fast track designation and orphan drug status granted by the FDA. Orphan Medicinal Product designation and positive Scientific Advice granted by the EMA .

AEZS-108: Orphan drug and Orphan medicinal product designations granted by the FDA and EMA respectively, for the treatment of ovarian cancer.

AEZS-130: Orphan drug designation granted by the FDA for use as a diagnostic test for AGHD.

As of December 2013, the company's Chief Commercial Officer is Jude Dinges.


Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q2 2019 2019-08-12 0.00 0.00
Q1 2019 2019-05-07 -0.30 -0.30
Q4 2018 2019-03-26 -0.31 -0.31
Q3 2018 2018-11-06 -0.15 -0.15
Q2 2018 2018-08-09 -0.16 -0.16
Q1 2018 2018-05-07 0.87 0.87
Q4 2017 2018-03-28 -0.24 -0.03
Q3 2017 2017-11-08 -0.61 -0.61
Q2 2017 2017-08-10 -0.18 -0.18
Q1 2017 2017-05-08 -0.31 -0.31

Ratings

2016-07-10 Reiterated Rating HC Wainwright Buy $12.00
2016-07-05 Reiterated Rating Maxim Group Buy $11.00
2016-06-15 Reiterated Rating Maxim Group Buy $11.00
2016-05-10 Reiterated Rating Maxim Group Buy $11.00
2016-05-02 Reiterated Rating Maxim Group Buy $11.00
2016-04-04 Reiterated Rating Canaccord Genuity Buy $13.00 to $9.00
2016-03-03 Reiterated Rating Maxim Group Buy $11.00
2016-01-20 Reiterated Rating Maxim Group Buy $11.00
2015-12-02 Reiterated Rating Canaccord Genuity Buy
2015-12-02 Boost Price Target HC Wainwright Buy $11.00 to $12.00
2015-11-25 Reiterated Rating Canaccord Genuity Buy $0.10 to $13.00
2015-11-09 Upgrade Canaccord Genuity Hold to Buy
2015-11-06 Reiterated Rating Maxim Group Buy $2.00
2015-10-13 Reiterated Rating Maxim Group Buy $2.00
2015-09-28 Reiterated Rating Maxim Group Buy $2.00
2015-08-18 Lower Price Target HC Wainwright Buy $1.25 to $1.00
2015-08-17 Initiated Coverage Canaccord Genuity Hold
2015-08-16 Reiterated Rating Maxim Group Buy
2015-07-28 Reiterated Rating Maxim Group Buy $2.00
2015-07-02 Reiterated Rating Maxim Group Buy
2015-06-17 Reiterated Rating Maxim Group Buy $2.00
2015-05-23 Reiterated Rating HC Wainwright Buy $1.25
2015-05-12 Reiterated Rating Canaccord Genuity Hold $0.70
2015-04-14 Upgrade HC Wainwright Neutral to Buy $1.25
2015-03-24 Reiterated Rating HC Wainwright Hold
2014-12-29 Set Price Target Maxim Group Buy $2.00
2014-11-10 Downgrade Maxim Group Sell
2014-11-06 Downgrade H.C. Wainwright Buy to Neutral
2014-11-06 Downgrade HC Wainwright Buy to Neutral
2014-07-17 Initiated H.C. Wainwright Buy $3
2014-07-17 Initiated Coverage HC Wainwright Buy $3.00
2013-01-03 Upgrade MLV & Co Hold to Buy $5.50
2012-10-09 Initiated Maxim Group Buy $9
2012-04-02 Downgrade MLV & Co Buy to Hold
2011-06-07 Initiated Oppenheimer Outperform $5.50
2011-04-27 Reiterated Canaccord Genuity Speculative Buy $2.75 to $4
2010-11-29 Initiated MLV Capital Buy $5.50
2009-02-05 Upgrade RBC Capital Mkts Sector Perform to Outperform
2008-06-03 Reiterated Canaccord Adams Buy $3.20 to $2.65
2008-04-14 Reiterated Canaccord Adams Buy $4.50 to $3.20
2007-10-03 Reiterated Rodman & Renshaw Mkt Outperform $8 to $6
2007-08-15 Upgrade RBC Capital Mkts Sector Perform to Outperform
2007-05-15 Initiated Oppenheimer Buy $7
2007-05-09 Reiterated Rodman & Renshaw Mkt Outperform $10 to $8
2016-07-10 Reiterated Rating HC Wainwright Buy $12.00
2016-07-05 Reiterated Rating Maxim Group Buy $11.00
2016-06-15 Reiterated Rating Maxim Group Buy $11.00
2016-05-10 Reiterated Rating Maxim Group Buy $11.00
2016-05-02 Reiterated Rating Maxim Group Buy $11.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In AEZS 0 funds of 2184 total. Show all

Fund name Ticker shares

Major Shareholders

Name Relationship Total Shares Holding stocks

Comments